

May 14, 2021

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Mothers)

Inquiries: Arihiko Bijohira, Executive Director & CFO

Phone: +81-3-6383-3746

Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development

Chiome Bioscience Inc. ("Chiome") announced today that Chiome and Mologic Ltd. ("Mologic", headquartered in Bedfordshire, United Kingdom) have entered into a Collaborative Research Agreement for antibody discovery and development for use in advanced diagnostic tests.

Under this Collaborative Research Agreement for up to 1 year, Chiome will generate specialised antibodies against several novel diagnostic biomarker targets by means of the ADLib® system, Chiome's proprietary antibody generation technology. "This technology is uniquely well suited to in vitro discovery of antibodies that recognize important but obscure or subtle antigenic features, which can make a positive difference to the performance of diagnostic tests.", commented Professor Paul Davis, Co-Founder and Chief Scientific Officer of Mologic. Mologic will characterize and evaluate the antibodies for application in its advanced diagnostic test platforms. Based on this comprehensive collaboration agreement, Chiome expects to directly contribute to Mologic's leading edge diagnostic work for maximum positive impact on global public health. There is a strong and growing demand for accurate and rapid diagnostic products throughout the world, especially in low to middle income countries (LMICs) suffering from a burden of debilitating infectious diseases, such as tuberculosis and malaria.

Chiome will receive research fees from Mologic, and royalties from the profit-making diagnostic products, based on the specialized properties of Chiome antibodies sold in the developed world. Full financial details are not being disclosed.

<About Mologic> (<https://mologic.co.uk/>)

Mologic is a leading developer of advanced lateral flow and rapid diagnostic technologies. Leveraging its core technology platforms, the Company works with global organisations, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-need.

Mologic offers world-leading technology and scientific research expertise for contract research and development, alongside a portfolio of device and reagent products for clinical applications. The Company also helps organisations to scale-up manufacturing from initial prototyping through low to mid-scale production. Mologic's science has broad application across markets and disease states where rapid, accurate point-of-need testing can help make a difference in patient care and patient outcomes.

Mologic is conducting innovative exploratory science for step change technology through its Centre for Advanced Rapid Diagnostics (CARD). The aim is to develop (and make accessible) the next-generation of ultra-sensitive point-of-need diagnostics which are easy to use and low cost to manufacture - critical to the success of many global health programmes.

<About ADLib® system technology>

The ADLib® system offers a platform library with unique array space that adds seamless Affinity maturation function. It is a rapid one stop order drug discovery and research tool that can complete

all the steps necessary for antibody drug discovery such as selection, full-length IgG expression, humanization, and affinity maturation on one *in-vitro* platform.